DMTK DermTech
- 0.500
- -0.072-12.54%
- 0.513
- +0.013+2.62%
DermTech News
10-Q: Quarterly report
DermTech Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
DermTech Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M
04:05 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M
DermTech 1Q Loss/Shr 58c >DMTK
DermTech 1Q Loss/Shr 58c >DMTK
Press Release: DermTech Reports First-Quarter 2024 Financial Results
DermTech Reports First-Quarter 2024 Financial Results - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus
What Analysts Are Saying About DermTech Stock
DermTech (NASDAQ:DMTK) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent ratings by
Lake Street Downgrades DermTech to Hold, Announces $0.63 Price Target
Lake Street analyst Thomas Flaten downgrades DermTech from Buy to Hold and announces $0.63 price target.
DermTech Price Target Maintained With a $1.50/Share by Stephens & Co.
DermTech Price Target Maintained With a $1.50/Share by Stephens & Co.
Stephens & Co. : The DermTech (DMTK.US) rating was reaffirmed and adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, with a target price of $1.50.
Stephens & Co. : The DermTech (DMTK.US) rating was reaffirmed and adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, with a target price of $1.50.
Stephens & Co. Reiterates Equal-Weight on DermTech, Maintains $1.5 Price Target
Stephens & Co. analyst Mason Carrico reiterates DermTech (NASDAQ:DMTK) with a Equal-Weight and maintains $1.5 price target.
DermTech Cut to Neutral From Buy by BTIG
DermTech Cut to Neutral From Buy by BTIG
BTIG Downgrades DermTech to Neutral
BTIG analyst Sung Ji Nam downgrades DermTech from Buy to Neutral.
DermTech (DMTK) Was Downgraded to a Hold Rating at BTIG
DermTech to Slash 56% of Workforce, Explore Options
By Ben Glickman DermTech said Thursday that it plans to cut more than half of its workforce as it explores strategic alternatives, its third round of layoffs in less than a year. The San Diego-based
Express News | DERMTECH will lay off approximately 56%, or 100 employees.
DermTech Intends To Continue Laboratory Operations During Strategic Review
The Company anticipates incurring a one-time restructuring charge of approximately $1.6 million in the second quarter of 2024 in connection with these restructuring actions. The company believes it ha
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that effe
BTIG Remains a Buy on DermTech (DMTK)
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024
Analysis
Price Target
No Data
